10 likes | 29 Views
The total prevalent population of Nontuberculous Mycobacteria Infection in 7MM is expected to be 3,95,429 by 2030. The United States accounts for approximately 49% of the total prevalent population in 7MM. The therapeutic market of Nontuberculous Mycobacteria Infection in 7MM is expected to grow at a CAGR of 6.6% during the study period. The key players in the Nontuberculous Mycobacteria Infection market include Insmed Inc., RedHill Biopharma, Novoteris, Savara Inc, Beyond Air and others. <br>For more information visit: <br>https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-ntm-infections-market<br><br><br><br>
E N D